secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENZ Therapeutics, Inc. (LENZ)
CIK:        0001815776
Form:       8-K
Filed at:   2021-12-08T23:59:59+00:00
Accession:  0001564590-21-059679
Event type: leadership
Sentiment:  negative
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Graphite Bio COO Katherine Stultz to depart effective Dec 31, 2021
------------------------------------------------------------------

- Katherine V. Stultz, Chief Operating Officer, agreed to end employment on December 31, 2021.
- Departure decision announced on December 6, 2021; no replacement named.
- No severance or compensatory details disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815776/000156459021059679/0001564590-21-059679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815776/000156459021059679/grph-8k_20211206.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-059679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer